Skip to main content
. 2020 May 6;37(2):91–97. doi: 10.4274/tjh.galenos.2019.2019.0254

Table 3. Response rate in patients treated with bortezomib-based regimens or conventional chemistry.

graphic file with name TJH-37-91-g3.jpg